Objective: This study aims to investigate the clinical effects of hydroxychloroquine adjuvant therapy in pregnant women with Systemic Lupus Erythematosus (SLE). Methods: A total of 78 pregnant women with SLE from February 2016 to August 2017 were recruited and divided into two groups, control (n=39) and observation (n=39), by using a random number table. The observation group received hydroxychloroquine adjuvant therapy, whereas the control group received conventional symptomatic treatment. The lupus activity during pregnancy, term birth rate, pregnancy and fetus outcomes, new-born Apgar score, and neonatal weight of the two groups were compared. Results: The occurrence rate of lupus during pregnancy in the observation group was 25.64%, which was significantly lower than that of the control group (51.28%) (P<0.05). The observation group achieved significantly higher term birth rate (84.62%) than the control group (58.97%) (P<0.05). The occurrence rates of bad pregnancy and fetus outcomes of the observation and control groups were 17.95% and 44.44%, respectively, which showed a significant difference (P<0.05). The new-born Apgar score and neonatal weight of the observation group were 9.61 ± 0.25 and 2.78 ± 0.56 kg, whereas those of the control group were 8.10 ± 0.31 and 2.47 ± 0.58 kg, showing a significant difference (P<0.05). Conclusions: Hydroxychloroquine adjuvant therapy exerts outstanding clinical effects to pregnant patients with SLE. This therapy not only improves pregnancy outcome but also reduces the occurrence of lupus. This method has a very high clinical application value and is worthy of further clinical research and applications.

Objective: To study the effects of pregnancy management in prognosis for pregnant patients with systemic lupus erythematosus (SLE). Methods: 217 pregnant patients who were diagnosed with SLE were divided into two groups, the control group and the intervention group. The intervention group was treated with routine treatment and nursing with additional pregnancy management, while the control group was treated with only routine treatment and nursing. Additionally, 195 normal pregnant women in the same period were selected as the healthy control. Regular laboratory tests were conducted for all subjects. Statistical analysis on changes of related disease indexes in each group was also performed. All information of maternal and neonatal outcomes was collected to record SLE activity rate, incidence of pregnancy induced hypertension (PIH), premature and fetal loss, neonatal weight and incidence of neonatal complications. Results: Increased ANA titer and dsDNA, lower immunoglobulin complement, renal damage, blood system damage, increased SLEDAI score and BILAG score were observed in the control group and the invention group compared with the healthy control. Both the control group and the intervention group showed significant increase in the incidences of PIH, premature delivery, fetal loss and neonatal complications as well as significant decrease in neonatal weight compared with the healthy control. SLE activity rate and incidences of PIH, premature delivery and neonatal complications were significantly decreased while neonatal weight was greatly increased in the intervention group compared with the control group. Results of logistic analysis showed that low immunoglobulin complement, renal damage, increased dsDNA, increased dsDNA and low immunoglobulin complement were independent risk factors for increased SLE activity rate, fetal loss, premature delivery and neonatal complications, respectively. Conclusion: The present study indicates that pregnancy management for pregnant SLE patients can significantly improve maternal and neonatal outcomes.